{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:48:13Z","timestamp":1789685293937,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]},{"name":"Natural Science Foundation of Beijing Municipality","award":["7232145"],"award-info":[{"award-number":["7232145"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the association of serum\u00a0anti-Jo-1 antibody  levels with the disease activity and prognosis in anti-Jo-1-positive patients with antisynthetase syndrome (ASS).\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study included 115 anti-Jo-1-positive patients with ASS who were admitted to China-Japan Friendship Hospital between 2009 and 2019. Anti-Jo-1 antibody serum levels at initial admission and follow-up were determined by enzyme-linked immunosorbent assay (ELISA). Global and organ disease activity was assessed at baseline and follow-up according to the International Myositis Assessment and Clinical Studies guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among enrolled patients, 70\u00a0(60.9%) patients initially presented with interstitial lung disease (ILD), and 46 (40%) patients\u00a0presented with\u00a0with muscle weakness\u00a0at initial admission. At baseline, patients with ILD had lower levels of anti-Jo-1 antibodies than those without ILD (<jats:italic>p<\/jats:italic>\u2009=\u20090.012). Baseline anti-Jo-1 antibody levels were higher in patients with muscle weakness, skin involvement, and arthritis (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) compared to those without these manifestations. Baseline anti-Jo-1 antibody levels were positively correlated with skin visual analogue scale (VAS) scores (<jats:italic>r<\/jats:italic>\u2009=\u20090.25, <jats:italic>p<\/jats:italic>\u2009=\u20090.006), but not with disease activity in other organs. However, changes in anti-Jo-1 antibody levels were significantly positively correlated with the changes in PGA (\u03b2\u2009=\u20090.002, <jats:italic>p<\/jats:italic>\u2009=\u20090.001), muscle (\u03b2\u2009=\u20090.003, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and pulmonary (\u03b2\u2009=\u20090.002, <jats:italic>p<\/jats:italic>\u2009=\u20090.013) VAS scores, but not with skin and joint VAS scores. Older age of onset (hazard ratio [HR] 1.069, 95% confidence interval [CI]:1.010\u20131.133, <jats:italic>p<\/jats:italic>\u2009=\u20090.022) and higher C-reactive protein (CRP) levels (HR 1.333, 95% CI: 1.035\u20131.717, <jats:italic>p<\/jats:italic>\u2009=\u20090.026) were risk factors for death.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Anti-Jo-1 titers appear to correlate more with disease activity changes over time rather than with organ involvement at baseline, which provides better clinical guidance for assessing the disease course using anti-Jo-1 levels.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-024-02851-w","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:02:29Z","timestamp":1716994949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and prognostic associations of anti-Jo-1 antibody levels in patients with antisynthetase syndrome"],"prefix":"10.1186","volume":"25","author":[{"given":"Hongxia","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwen","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"2851_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00234-1","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Prim. 2021;7:1\u201322.","journal-title":"Nat Rev Dis Prim"},{"key":"2851_CR2","doi-asserted-by":"publisher","first-page":"101503","DOI":"10.1016\/j.berh.2020.101503","volume":"34","author":"JL Marco","year":"2020","unstructured":"Marco JL, Collins BF. Clinical manifestations and treatment of antisynthetase syndrome. Best Pract Res Clin Rheumatol. 2020;34:101503.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2851_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK. Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35. Years? Chest. 2010;138:1464\u201374.","journal-title":"Years? Chest"},{"key":"2851_CR4","doi-asserted-by":"publisher","first-page":"103204","DOI":"10.1016\/j.autrev.2022.103204","volume":"21","author":"Y Muro","year":"2022","unstructured":"Muro Y, Yamashita Y, Koizumi H, Ogawa-Momohara M, Takeichi T, Mitsuma T, et al. Two novel anti-aminoacyl tRNA synthetase antibodies: autoantibodies against cysteinyl-tRNA synthetase and valyl-tRNA synthetase. Autoimmun Rev. 2022;21:103204.","journal-title":"Autoimmun Rev"},{"key":"2851_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","volume":"14","author":"NJ McHugh","year":"2018","unstructured":"McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14:290\u2013302.","journal-title":"Nat Rev Rheumatol"},{"key":"2851_CR6","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/00002281-200111000-00004","volume":"13","author":"GJD Hengstman","year":"2001","unstructured":"Hengstman GJD, Engelen BGM, Van V, Egberts WTM, Van Venrooij WJ. Myositis-specific autoantibodies: overview and recent developments. Curr Opin Rheumatol. 2001;13:476\u201382.","journal-title":"Curr Opin Rheumatol"},{"key":"2851_CR7","doi-asserted-by":"crossref","unstructured":"Vulsteke J-B, Derua R, Dubucquoi S, Coutant F, Sanges S, Goncalves D, et al. Mass spectrometry\u00ad based identification of new anti\u00ad Ly and known antisynthetase autoantibodies. Ann Rheum Dis. 2023;82:546\u201355.","DOI":"10.1136\/ard-2022-222686"},{"key":"2851_CR8","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai M, Reichlin M. Heterogeneity of precipitating ntibodies characterization of the Jo- 1 antibody system. Arthritis Rheum. 1980;23:881\u20138.","journal-title":"Arthritis Rheum"},{"key":"2851_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-022-02745-6","volume":"24","author":"A Notarnicola","year":"2022","unstructured":"Notarnicola A, Preger C, Lundstr\u00f6m SL, Renard N, Wigren E, Gompel E, Van, et al. Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome. Arthritis Res Ther. 2022;24:1\u201316.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2851_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2397198320902667","volume":"5","author":"K Huang","year":"2020","unstructured":"Huang K, Aggarwal R. Antisynthetase syndrome: a distinct disease spectrum. J Scleroderma Relat Disord. 2020;5(3):178\u201391.","journal-title":"J Scleroderma Relat Disord"},{"key":"2851_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","volume":"46","author":"Trallero-aragu\u00e1sE Grau-junyent","year":"2016","unstructured":"Grau-junyent Trallero-aragu\u00e1sE, Monteagudo-jim\u00e9nez JM, Fraile-rodriguez M. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients Study Group and Autoimmune Diseases Study Group (GEAS) of the Spanish Society of. Semin Arthritis Rheum. 2016;46:225\u201331.","journal-title":"Semin Arthritis Rheum"},{"key":"2851_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","volume":"30","author":"L Gallay","year":"2018","unstructured":"Gallay L, Gayed C, Hervier B. Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol. 2018;30:664\u201373.","journal-title":"Curr Opin Rheumatol"},{"key":"2851_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/BOR.0000000000000663","volume":"31","author":"M Gasparotto","year":"2019","unstructured":"Gasparotto M, Gatto M, Saccon F, Ghirardello A, Iaccarino L, Doria A. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol. 2019;31:603\u201310.","journal-title":"Curr Opin Rheumatol"},{"key":"2851_CR14","doi-asserted-by":"crossref","unstructured":"Marie I, Josse S, Hatron PY, Dominique S, Hachulla E, Janvresse A, et al. Interstitial lung disease in anti \u2013 Jo-1 patients with antisynthetase syndrome. Arthritis Care Res (Hoboken). 2013;65:800\u20138.","DOI":"10.1002\/acr.21895"},{"key":"2851_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","volume":"118","author":"AC Zamora","year":"2016","unstructured":"Zamora AC, Hoskote SS, Abascal-bolado B, White D, Cox CW, Ryu JH, et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016;118:39\u201345.","journal-title":"Respir Med"},{"issue":"1","key":"2851_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/art.41075","volume":"72","author":"AS Galindo-Feria","year":"2020","unstructured":"Galindo-Feria AS, Albrecht I, Fernandes-Cerqueira C, Notarnicola A, James EA, Herrath J, et al. Proinflammatory histidyl-transfer RNA synthetase-specific CD4 + T cells in the blood and lungs of patients with idiopathic inflammatory myopathies. Arthritis Rheumatol. 2020;72(1):179\u201391.","journal-title":"Arthritis Rheumatol"},{"key":"2851_CR17","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20020186","volume":"196","author":"OM Zack Howard","year":"2002","unstructured":"Zack Howard OM, Dong HF, Yang De, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196:781\u201391.","journal-title":"J Exp Med"},{"key":"2851_CR18","doi-asserted-by":"publisher","first-page":"7127","DOI":"10.4049\/jimmunol.169.12.7127","volume":"169","author":"DP Ascherman","year":"2002","unstructured":"Ascherman DP, Oriss TB, Oddis CV, Wright TM. Critical requirement for Professional APCs in eliciting T cell responses to novel fragments of Histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis. J Immunol. 2002;169:7127\u201334.","journal-title":"J Immunol"},{"key":"2851_CR19","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1172\/JCI114461","volume":"85","author":"FW Miller","year":"1990","unstructured":"Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-jo-1 autoantibodies. J Clin Invest. 1990;85:468\u201375.","journal-title":"J Clin Invest"},{"key":"2851_CR20","doi-asserted-by":"crossref","unstructured":"Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti \u2013 Jo-1 antibody levels correlate with Disease Activity in Idiopathic Inflammatory Myopathy. Arthritis Rheum. 2007;56:3125\u201331.","DOI":"10.1002\/art.22865"},{"key":"2851_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-018-1650-8","volume":"20","author":"O Kry\u0161tufkov\u00e1","year":"2018","unstructured":"Kry\u0161tufkov\u00e1 O, Hulejov\u00e1 H, Mann HF, Pecha O, Putov\u00e1 I, Ekholm L, et al. Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1 positive polymyositis and dermatomyositis. Arthritis Res Ther. 2018;20:1\u201313.","journal-title":"Arthritis Res Ther"},{"key":"2851_CR22","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"2851_CR23","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1002\/art.23963","volume":"58","author":"SM Sultan","year":"2008","unstructured":"Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum. 2008;58:3593\u20139.","journal-title":"Arthritis Rheum"},{"key":"2851_CR24","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/acr.20532","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis. Arthritis Care Res. 2011;63:118\u201357.","journal-title":"Arthritis Care Res"},{"key":"2851_CR25","doi-asserted-by":"crossref","unstructured":"Miller FW. New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis 2012;71(Supp II):i82\u20135.","DOI":"10.1136\/annrheumdis-2011-200587"},{"key":"2851_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.autrev.2017.01.008","volume":"16","author":"E Bartoloni","year":"2017","unstructured":"Bartoloni E, Gonzalez-Gay MA, Scir\u00e8 C, Castaneda S, Gerli R, Lopez-Longo FJ, et al. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: results from a multicenter, international and retrospective study. Autoimmun Rev. 2017;16:253\u20137.","journal-title":"Autoimmun Rev"},{"key":"2851_CR27","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.str.2012.08.001","volume":"20","author":"Z Xu","year":"2012","unstructured":"Xu Z, Wei Z, Zhou JJ, Ye F, Lo WS, Wang F, et al. Internally deleted human tRNA synthetase suggests evolutionary pressure for repurposing. Structure. 2012;20:1470\u20137.","journal-title":"Structure"},{"key":"2851_CR28","doi-asserted-by":"publisher","first-page":"19269","DOI":"10.1074\/jbc.C114.571026","volume":"289","author":"JJ Zhou","year":"2014","unstructured":"Zhou JJ, Wang F, Xu Z, Lo WS, Lau CF, Chiang KP, et al. Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis. J Biol Chem. 2014;289:19269\u201375.","journal-title":"J Biol Chem"},{"key":"2851_CR29","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1002\/art.22790","volume":"56","author":"SM Levine","year":"2007","unstructured":"Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum. 2007;56:2729\u201339.","journal-title":"Arthritis Rheum"},{"key":"2851_CR30","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/acr.24993","volume":"75","author":"W Jiang","year":"2023","unstructured":"Jiang W, Shi J, Yang H, Tian X, Yang H, Chen Q, et al. Long-term outcomes and prognosis factors in patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies: a single cohort study. Arthritis Care Res. 2023;75:1175\u201382.","journal-title":"Arthritis Care Res"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02851-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02851-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T15:04:20Z","timestamp":1716995060000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02851-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2851"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02851-w","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]},"assertion":[{"value":"10 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients completed informed consent forms, and the study was approved by the Research Review Committee and the Ethical Review Committee of the China-Japan Friendship Hospital (approval number 2019-SDZL-3). And this study was conducted in accordance with the Declaration of Helsinki guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}